 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- |||| AGN-223575 / AbbVie
Trial completion: Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease (clinicaltrials.gov) - Feb 24, 2016
P2, N=236, Completed, Sponsor: Allergan
Active, not recruiting --> Completed
- ||| AGN-223575 / AbbVie
Enrollment closed, Enrollment change, Trial primary completion date: Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease (clinicaltrials.gov) - Jan 11, 2016
P2, N=236, Active, not recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=168 --> 236 | Trial primary completion date: Nov 2016 --> Jan 2016
- |||| AGN-223575 / AbbVie
Enrollment open: Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease (clinicaltrials.gov) - Jul 31, 2015
P2, N=168, Recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting | N=168 --> 236 | Trial primary completion date: Nov 2016 --> Jan 2016 Not yet recruiting --> Recruiting
- ||||| AGN-223575 / AbbVie
New P2 trial: Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease (clinicaltrials.gov) - May 6, 2015
P2, N=168, Not yet recruiting, Sponsor: Allergan
- ||| AGN-223575 / AbbVie
Trial completion: A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects (clinicaltrials.gov) - Mar 17, 2015
P1, N=51, Completed, Sponsor: Allergan
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || AGN-223575 / AbbVie
Enrollment closed, Enrollment change: A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects (clinicaltrials.gov) - Dec 12, 2014
P1, N=51, Active, not recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=39 --> 51
- | AGN-223575 / AbbVie
New P1 trial: A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects (clinicaltrials.gov) - Jun 2, 2014
P1, N=39, Recruiting, Sponsor: Allergan